# Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

> **NCT03485911** · PHASE3 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 121 (actual)

## Conditions studied

- Hereditary Angioedema
- HAE

## Interventions

- **DRUG:** BCX7353 capsules
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03485911
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2019-04-10
- **Final completion:** 2022-04-06
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485911, "Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03485911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*